WASHINGTON | biotech american Moderna announced on Tuesday that it would enter the 27 July in the final phase of its clinical trials for a vaccine against the Covid-19, becoming the first company in the world to achieve this step.
30 000 people will participate in this decisive phase in the United States; half of them will receive a dose of 100 micrograms, the other a placebo.
The primary purpose of this essay will be to prevent any symptoms of Covid-19. Its secondary objectives include the prevention of an infection with the SARS-CoV-2.
This study is expected to last until 27 October.
The advert placed Moderna head of the global race for a vaccine against this disease that has infected more than 13 million people in the world, and more than 570 000 people dead.
Scientists warn, however, that the first vaccines arriving on the market are not necessarily the most effective or the safest.
The technology of Moderna, which is based on messenger RNA, is designed to give the body the genetic information needed to trigger preventive protection against the coronavirus.